Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04212221

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Advanced Hepatocellular Carcinoma (HCC) Clinical Trial

Official title:
A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination With Brivanib Alaninate (ZL-2301) in Patients With Advanced Liver Cancer

Clinical Trial Summary

This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects with advanced liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma). Phase II is a dose expansion study and consists of two parts: Part 1 is to assess the safety and efficacy of MGD013 monotherapy and MGD013 in combination with ZL-2301 in subjects with advanced hepatocellular carcinoma (HCC); in Part 2, a therapeutic method (MGD013 monotherapy or MGD013 in combination with ZL-2301, determined by the sponsor according to the obtained data) will be selected for dose expansion study in HCC subjects who have previously failed immune checkpoint inhibitor treatment, to further evaluate the safety and efficacy of the study treatments in the specific group of subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04212221
Study type Interventional
Source Zai Lab (Hong Kong), Ltd.
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date April 20, 2020
Completion date April 27, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04985136 - A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) Phase 3
Recruiting NCT02509169 - Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT04723004 - Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC Phase 3
Completed NCT02814461 - The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC Phase 1
Not yet recruiting NCT04344158 - A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Phase 3
Completed NCT02906397 - Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) Phase 1
Active, not recruiting NCT04523493 - Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC Phase 3
Terminated NCT05375604 - A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) Phase 1
Terminated NCT01101906 - A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC Phase 2
Recruiting NCT05862181 - The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Not yet recruiting NCT06309485 - Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC Phase 2
Active, not recruiting NCT04605796 - A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) Phase 2